ProCE Banner Activity

Optimal Integration of Checkpoint Inhibitors Into the Management of Unresectable Stage III NSCLC

Slideset Download
In this downloadable slideset, Mark M. Awad, MD, PhD, and Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd, juxtapose historical data for concurrent CRT with new evidence for immune checkpoint therapy in the care of patients with stage III NSCLC.

Released: April 27, 2018

Expiration: April 26, 2019

No longer available for credit.

Share

Faculty

Mark M. Awad

Mark M. Awad, MD, PhD

Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Tarek Mekhail

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd

Medical Director, Thoracic Cancer Program
Florida Hospital Medical Group
Orlando, Florida

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Mark M. Awad, MD, PhD

Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd

Medical Director, Thoracic Cancer Program
Florida Hospital Medical Group
Orlando, Florida